Myovant Sciences Ltd. (MYOV)

Market Cap	2.61B
Revenue (ttm)	379.11M
Net Income (ttm)	-183.77M
Shares Out	97.10M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	535,588
Open	26.88
Previous Close	26.90
Day's Range	26.87 - 26.90
52-Week Range	7.67 - 27.03
Beta	2.20
Analysts	Buy
Price Target	27.54 (+2.46%)
Earnings Date	Jan 26, 2023

About MYOV

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduc...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Lynn Seely
• Employees: 579
• Stock Exchange: NYSE
• Ticker Symbol: MYOV

Financial Performance

In 2022, MYOV's revenue was $230.97 million, an increase of 289.39% compared to the previous year's $59.32 million. Losses were -$205.98 million, -19.27% less than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is $27.54, which is an increase of 2.46% from the latest price.

Price Target

$27.54

(2.46% upside)

Analyst Consensus: Buy